Citius Oncology receives Nasdaq deficiency notice for bid price below $1.00

CITIUS ONCOLOGY, INC.

Nasdaq notified Citius Oncology that its common stock bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until October 20, 2025) to regain compliance with the Bid Price Rule.
If stock closes at $1.00 or more for ten consecutive business days, Nasdaq will confirm compliance.
If not compliant by October 20, 2025, the Company may be eligible for an additional 180-day period, subject to conditions.
Company is evaluating options, including a potential reverse stock split, to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.